Abstracts tagged "etanercept"

Abstract Number: 442 • 2015 ACR/ARHP Annual Meeting
Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As a proposed inflammatory biomarker for autoimmune disease1,2, the autonomic nervous system (ANS) has been assessed as a predictor of anti-TNF treatment outcome3 and…
Abstract Number: 2825 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel^®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA)
Sang-Cheol Bae¹, Jinseok Kim², Jung-Yoon Choe³, Won Park⁴, So-Ra Lee⁵, Yongho Ahn⁶ and Yunjeong Seo⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Internal Medicine, Jeju National University, Jeju, Korea, South Korea, ³Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁵Clinical Development/Regulatory Affairs, Hanwha Chemical, Seoul, South Korea, ⁶R&D Center, Hanwha Chemical, Daejeon, South Korea, ⁷Clinical Development, Hanwha Chemical, Seoul, South Korea
Background/Purpose Etanercept is a recombinant fusion protein that blocks TNF activity. HD203 is a biosimilar of etanercept. In a double-blind, randomized study in healthy volunteers,…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 2414 • 2014 ACR/ARHP Annual Meeting
Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study
Karl Heinz Goettl¹, Markus Gaubitz², Andreas Krause³, Udo Lendl⁴, Ralph Lippe⁴, Thomas Meng⁴ and Peter-Andreas Loeschmann⁵, ¹Joint practice for internal medicine, Passau, Germany, ²Academy of manual diagnostic at University of Münster, Münster, Germany, ³Konigstr. 63, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany, ⁵Loeschmann, Berlin, Germany
Background/Purpose Although a combination with MTX is recommended for all biologics, data from different registries around the world show that in real life around 30%…
Abstract Number: 2365 • 2014 ACR/ARHP Annual Meeting
Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept
Richard Martin¹, Ryan Enck², Andrew J. Head³, James Birmingham¹ and Aaron T. Eggebeen⁴, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University College of Human Medicine, Grand Rapids, MI, ³Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ⁴Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: To evaluate the comparative effects of a pharmaceutical industry decision guide (Pharm Booklet) and International Patient Decision Aids Standard (IPDAS) compliant patient decision aids…
Abstract Number: 2043 • 2014 ACR/ARHP Annual Meeting
How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists?
Aysa Hacioglu¹, Yesim Ozguler², Sermin Borekci³, Vedat Hamuryudan¹, Hanefi Deniz Kecebas¹, Ethem Koray Tascilar², Melike Melikoglu⁴, Serdal Ugurlu¹, Emire Seyahi¹, Izzet Fresko², Huri Ozdogan¹, Sebahattin Yurdakul¹, Gul Ongen³ and Gulen Hatemi¹, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³University of Istanbul, Cerrahpasa Medical Faculty, Department of Pulmonary Diseases, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: During the development of algorythms for screening latent tuberculosis before starting TNF-alpha antagonists, it is assumed that BCG vaccination causes false positive PPD and…
Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
Abstract Number: 1558 • 2014 ACR/ARHP Annual Meeting
Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response
M Dougados¹, H Jones², A Szumski³, I Logeart⁴ and J Coindreau⁵, ¹Université Paris René Descartes and Hôpital Cochin, Paris, France, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer, Paris, France, ⁵Pfizer Inc., New York, NY
Background/Purpose: Differentiating between pain related to spondyloarthritis (in particular polyenthesitis) and pain related to fibromyalgia can be challenging, both in daily practice and in clinical…
Abstract Number: 502 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab
Denis Choquette¹, Marie-Pier Payette¹, Jean-Pierre Raynauld¹, Jean-Pierre Pelletier², Louis Bessette³, Edith Villeneuve¹, Boulos Haraoui¹, Isabelle Fortin⁴, Marie-Anaïs Rémillard⁵, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ³Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁵Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…
Abstract Number: 485 • 2014 ACR/ARHP Annual Meeting
Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Simon Julius Winkelmann¹, Rainald A. Zeuner¹, Dörte Schuldt¹, Johannes Bethge¹, Ulrich Mrowietz², Matthias Laudes¹, Stefan Schreiber¹ and Johann Schroeder¹, ¹1st Medical Dept, University of Kiel, Kiel, Germany, ²Dermatology, Univ Schleswig-Holstein, Kiel, Germany
Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of…
Abstract Number: 492 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
J. Carter Thorne¹, Edward C. Keystone², Janet E. Pope³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁵ and Boulos Haraoui⁶, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³St Joseph Health Care, London, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The Canadian Methotrexate and Etanercept Outcome Study (CAMEO) evaluated etanercept (ETN) monotherapy vs ETN plus methotrexate (MTX) in biologic-naïve patients with rheumatoid arthritis…
Abstract Number: 286 • 2014 ACR/ARHP Annual Meeting
Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study
Katherine Green¹, Marinka Twilt² and Taunton R. Southwood³, ¹Rheumatology, Birmingham Children's Hospital, Birmingham, United Kingdom, ²Paediatrics, Aarhus University Hospital, Aarhus, Denmark, ³Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom
Background/Purpose The 2011 ACR recommendations for the treatment of Juvenile Idiopathic Arthritis (ACR-JIA) are evidence-based, consensus-approved therapeutic pathways for the safe and effective treatment of…
Abstract Number: 285 • 2014 ACR/ARHP Annual Meeting
Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Gerd Horneff¹, Hans Huppertz², Gerd Ganser³, Johannes Peter Haas⁴, Ivan Foeldvari⁵ and Kirsten Minden⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²Prof Hess Children’s Hospital, Bremen, Germany, ³Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁴German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶Epidemiology unit, German Rheumatism Research Center, Berlin, Germany
Background/Purpose Drug surveillance of biologics in juvenile patients using registries is of immense importance as patient numbers and duration in clinical trials are limited. There…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].